Royal Emerald Pharmaceuticals (REP) is proud to announce that it has received four federal licenses to grow, research, develop, and manufacture alternative drugs derived from cannabis (marijuana) and other botanicals in December 2021. REP is the first-of-its-kind cannabis pharmaceutical company in the United States to receive these highly coveted licenses. The Drug Enforcement Administration (DEA) issued three licenses for bulk manufacturing, analytical lab, and import in December. Advertisement An earlier license was issued for distribution. Now, REP has all four federal (DEA) licenses needed to move forward with their next phase of development. This latest move by the DEA is a clear message that the federal government is loosening its grip on marijuana specifically grown for research purposes. It has been a long and hard battle for entrepreneurs in the cannabis industry to win approval from the DEA, but now it has finally happened. “We are excited and very happy to receive these DEA licenses for cannabis research,” said Mark Crozier, Founder, and CEO of Royal Emerald Pharmaceuticals. “We are excited and very happy to receive these DEA licenses for cannabis research,” said Mark Crozier, Founder, and CEO of Royal Emerald Pharmaceuticals. “This news is huge and comes with immense responsibilities – we have been chosen to provide researchers and universities with high-quality cannabis so they can move forward with their research projects. These researchers have struggled for decades to be recognized by the medical and scientific communities. Now, they can,” Crozier said.
mg Magazine – Cannabis News & Information, 01/24/2022 10:48:00